Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 1/20 | 0.48 |
| ▸ | ARG1 | P05089 | 1/20 | 0.44 |
| ▸ | ARG2 | P78540 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7707996 | 0.81 | GGT1 (0.50) | GGT1ARG1ARG2GRM4BLM | |
| SCHEMBL179781 | 0.81 | GRM4 (0.61) | GGT1ARG1ARG2GRM4BLM | |
| SCHEMBL13745593 | 0.81 | GRM4 (0.61) | GGT1ARG1ARG2GRM4BLM | |
| SCHEMBL179782 | 0.81 | GRM4 (0.61) | GGT1ARG1ARG2GRM4BLM | |
| SCHEMBL5065224 | 0.78 | GGT1 (0.47) | GGT1ARG1ARG2GRM4BLM | |
| SCHEMBL8687592 | 0.77 | GGT1 (0.65) | GGT1ARG1ARG2BLMALDH1A1 | |
| SCHEMBL5065225 | 0.73 | GGT1 (0.43) | GGT1ARG1ARG2GRM4BLM | |
| SCHEMBL8688802 | 0.72 | ARG2 (0.72) | GGT1ARG1ARG2BLMALDH1A1 | |
| SCHEMBL9507610 | 0.72 | GGT1 (0.46) | GGT1ARG1ARG2GRM4BLM | |
| SCHEMBL5323056 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | KIACTA SARL (CH) | 2006-06-01 | — | — | US | disclosed |
| US-6670399-B2 | Contacting a blood vessel wall cell with an A beta 40 inhibitor, such that cerebral amyloid angiopathy is inhibited | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2003-12-30 | — | — | US | disclosed |
| EP-1251837-A2 | COMPOUNDS AND METHODS FOR MODULATING CEREBRAL AMYLOID ANGIOPATHY | Neurochem, Inc. (CA) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001085093-A2 | COMPOUNDS AND METHODS FOR MODULATING CEREBRAL AMYLOID ANGIOPATHY | NEUROCHEM, INC. (US) | 2001-11-15 | — | — | WO | disclosed |
| EP-1077690-A1 | USE OF AMYLOID INHIBITORS FOR MODULATING NEURONAL CELL DEATH | Neurochem, Inc. (CA) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059571-A1 | USE OF AMYLOID INHIBITORS FOR MODULATING NEURONAL CELL DEATH | NEUROCHEM, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | APP, PYGB, MAPT | GGT1 2558/4885ARG1 544/4885ARG2 296/4885 |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CSGALNACT1, CD44 | GGT1 736/4885ARG1 1700/4885ARG2 3728/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | GGT1 850/4885ARG1 1808/4885ARG2 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.